Patents by Inventor Yunfu Luo

Yunfu Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325907
    Abstract: Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 10, 2022
    Assignee: Medshine Discovery Inc.
    Inventors: Maoyi Lei, Yu Xu, Yunfu Luo
  • Patent number: 11319305
    Abstract: Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: May 3, 2022
    Assignee: Shijiazhuang Sagacity New Drug Development Co., Ltd.
    Inventors: Yunfu Luo, Maoyi Lei, Junmiao Li, Yu Xu, Ran Wei, Shuhui Chen
  • Patent number: 11319330
    Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: May 3, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Maoyi Lei, Yunfu Luo, Yu Xu, Guoli Zhang, Jinghong Dong, Jian Li, Shuhui Chen
  • Publication number: 20220119376
    Abstract: The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2019
    Publication date: April 21, 2022
    Inventors: Maoyi Lei, Yunfu Luo, Yu Xu, Guoli Zhang, Zhijuan Yu, Jian Li, Shuhui Chen
  • Publication number: 20210393627
    Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.
    Type: Application
    Filed: June 5, 2019
    Publication date: December 23, 2021
    Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.
    Inventors: Kunlun HE, Xiaojian GAO, Chunlei LIU, Zeyu ZHANG, Xin LI, Chen LI, Yunfu LUO, Maoyi LEI, Junmiao LI, Yiwei WANG
  • Patent number: 11155523
    Abstract: Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: October 26, 2021
    Assignee: Medshine Discovery, Inc.
    Inventors: Yunfu Luo, Yuyong Ba, Shuhui Chen
  • Publication number: 20210323960
    Abstract: Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 21, 2021
    Inventors: Yunfu LUO, Jianfeng PAN, Guoli ZHANG, Sheng SU, Yong WANG, Shuhui CHEN
  • Publication number: 20210317138
    Abstract: Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2019
    Publication date: October 14, 2021
    Inventors: Maoyi LEI, Yunfu LUO, Yu XU, Guoli ZHANG, Jinghong DONG, Jian LI, Shuhui CHEN
  • Publication number: 20210317109
    Abstract: Disclosed is a series of tricyclic substituted piperidine dione compounds, and applications thereof in the preparation of medicines for treating diseases related to CRBN protein; specifically disclosed are the derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 9, 2019
    Publication date: October 14, 2021
    Inventors: Yunfu LUO, Maoyi LEI, Yong WANG, Jian LI, Shuhui CHEN
  • Patent number: 11136315
    Abstract: A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 5, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Bin Chen, Xiawei Wei, Xuefeng Sun, Lei Zhang, Zhaoying Xu, Wenli Li, Peng Zhang, Feng Gao, Yunfu Luo, Jian Li, Shuhui Chen
  • Publication number: 20210198253
    Abstract: Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor.
    Type: Application
    Filed: January 29, 2019
    Publication date: July 1, 2021
    Inventors: Maoyi LEI, Yu XU, Yunfu LUO
  • Publication number: 20200339549
    Abstract: A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2019
    Publication date: October 29, 2020
    Inventors: Bin CHEN, Xiawei WEI, Xuefeng SUN, Lei ZHANG, Zhaoying XU, Wenli LI, Peng ZHANG, Feng GAO, Yunfu LUO, Jian LI, Shuhui CHEN
  • Publication number: 20200283425
    Abstract: Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.
    Type: Application
    Filed: November 19, 2018
    Publication date: September 10, 2020
    Inventors: Yunfu LUO, Maoyi LEI, Junmiao LI, Yu XU, Ran WEI, Shuhui CHEN
  • Patent number: 10745377
    Abstract: The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 18, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana M. Maletic, Yunfu Luo, Zhiqi Qi, Tingting Yu, Richard Soll
  • Publication number: 20200223801
    Abstract: Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 16, 2020
    Inventors: Yunfu LUO, Yuyong BA, Shuhui CHEN
  • Patent number: 10662189
    Abstract: Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 26, 2020
    Assignee: SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Ling Liu, Guoping Hu, Jian Li, Shuhui Chen
  • Publication number: 20200076283
    Abstract: A method for inserting insulating sleeves into wiring slots of a flat wire motor stator, including: S1: selecting a plurality of insulating sleeves matched with a size of wiring slots of a flat wire motor stator, and pre-processing the insulating sleeves to a length by cutting according to a size of the flat wire motor stator; S2: conveying the pre-processed insulating sleeves, through a conveying mechanism, to a positioning mechanism located behind the conveying mechanism; S3: clamping the insulating sleeves in the positioning mechanism above the wiring slots of the flat wire motor stator by a clamping mechanism; S4: moving a guide mechanism above the flat wire motor stator in the positioning plate set, where S4 is synchronized with S3; S5: repeating S1 to S7 until the space factor of the wiring slots of the flat wire motor stator reaches the set value.
    Type: Application
    Filed: July 8, 2019
    Publication date: March 5, 2020
    Inventors: Qilong LU, Yunfu LUO, Yibing XIONG, Fangliang HE, Qiusheng CHENG
  • Patent number: 10532986
    Abstract: Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 14, 2020
    Assignee: Medshine Discovery Inc.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Lanbao Sun, Guoping Hu, Jian Li, Shuhui Chen
  • Patent number: 10526336
    Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 7, 2020
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
  • Patent number: 10435398
    Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: October 8, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo